These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25231191)

  • 21. Variation in antidiabetic medication intensity among Medicare beneficiaries with diabetes mellitus.
    Stuart B; Shaffer TJ; Simoni-Wastila LJ; Zuckerman IH; Quinn CC
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):195-208. PubMed ID: 17996659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database.
    Simeone JC; Quilliam BJ
    Ann Pharmacother; 2012 Feb; 46(2):157-68. PubMed ID: 22234990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.
    Bodmer M; Becker C; Meier C; Jick SS; Meier CR
    Am J Gastroenterol; 2012 Apr; 107(4):620-6. PubMed ID: 22290402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do we have enough data to confirm the link between antidiabetic drug use and cancer development?
    Drzewoski J; Drozdowska A; Sliwińska A
    Pol Arch Med Wewn; 2011 Mar; 121(3):81-7. PubMed ID: 21430609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin--carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research.
    Call R; Grimsley M; Cadwallader L; Cialone L; Hill M; Hreish V; King ST; Riche DM
    Postgrad Med; 2010 May; 122(3):158-65. PubMed ID: 20463425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data.
    Bykov K; He M; Franklin JM; Garry EM; Seeger JD; Patorno E
    Diabetes Obes Metab; 2019 Sep; 21(9):2029-2038. PubMed ID: 31062453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis.
    Cheung B; Fei Y; Tsoi MF
    Eur Cardiol; 2020 Feb; 15():e40. PubMed ID: 32612700
    [No Abstract]   [Full Text] [Related]  

  • 29. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
    Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
    Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
    Ryder RE
    Diabet Med; 2015 Mar; 32(3):305-13. PubMed ID: 25472014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.
    Varas-Lorenzo C; Margulis AV; Pladevall M; Riera-Guardia N; Calingaert B; Hazell L; Romio S; Perez-Gutthann S
    BMC Cardiovasc Disord; 2014 Sep; 14():129. PubMed ID: 25260374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
    Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
    JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II.
    Cetrone M; Mele A; Tricarico D
    Curr Diabetes Rev; 2014; 10(4):231-7. PubMed ID: 25245021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
    Herrigel DJ; Moss RA
    Postgrad Med; 2014 Oct; 126(6):106-18. PubMed ID: 25414939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole transcriptome microarrays identify long non-coding RNAs associated with cardiac hypertrophy.
    Zhang L; Hamad EA; Vausort M; Funakoshi H; Nicot N; Nazarov PV; Vallar L; Feldman AM; Wagner DR; Devaux Y;
    Genom Data; 2015 Sep; 5():68-71. PubMed ID: 26484228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
    Sykes AP; Kemp GL; Dobbins R; O'Connor-Semmes R; Almond SR; Wilkison WO; Walker S; Kler L
    Diabetes Obes Metab; 2015 Jan; 17(1):98-101. PubMed ID: 25238025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study.
    Zanchi A; Tappy L; Lê KA; Bortolotti M; Theumann N; Halabi G; Gauthier T; Mathieu C; Tremblay S; Bertrand PC; Burnier M; Teta D
    PLoS One; 2014; 9(10):e109134. PubMed ID: 25330088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?
    Baran B; Akyüz F
    World J Gastroenterol; 2014 Oct; 20(39):14219-29. PubMed ID: 25339808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.